According to Oppenheimer, Lincare Holdings LNCR reported 1Q11 EPS of $0.49, in line with estimate and consensus.
Oppenheimer reported that results were generally in line, as a slightly lower tax rate (+$0.01) and share count offset some margin pressure. “During the quarter, the company acquired a specialty pharmacy business ($82M annual revenues), which contributed approximately $9M in revenues in 1Q11. We have consequently tweaked our model for the acquisition, and while our FY2011 EPS estimate is unchanged at $2.10, we are increasing our FY2012 estimate from $2.36 to $2.38. Furthermore, we are increasing our price target to $29 from $28.”
Lincare Holdings closed yesterday at $30.76.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in